CXCL12 expression promotes esophageal squamous cell carcinoma proliferation and worsens the prognosis
Authors:
- Yusuke UchiYUYusuke Uchi
- Hiroya TakeuchiHTHiroya Takeuchi
- Sachiko MatsudaSMSachiko Matsuda
- Yoshiro SaikawaYSYoshiro Saikawa
- Hirofumi KawakuboHKHirofumi Kawakubo
- Norihito WadaNWNorihito Wada
- Tsunehiro TakahashiTTTsunehiro Takahashi
- Rieko NakamuraRNRieko Nakamura
- Kazumasa FukudaKFKazumasa Fukuda
- Tai OmoriTOTai Omori
- Yuko KitagawaYKYuko Kitagawa
Open Access
- 21 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-11
Abstract
The chemokine CXCL12 and its corresponding receptor CXCR4 are key players in the development of several cancers. Therefore, we hypothesized that there is a functional causality between CXCL12 expression and tumor progression in patients with esophageal squamous cell carcinoma (ESCC). We performed an immunohistochemical analysis in 79 consecutive patients with ESCC. We performed in vitro and in vivo cell proliferation assays using ESCC cell lines and a newly established transfectant stably overexpressing CXCL12. Immunohistochemistry revealed positive CXCR4 and CXCL12 expression in 48 (61 %) and 62 (78 %) patients, respectively. Additionally, the expression levels did not significantly correlate with any clinicopathological factors. The MIB-1 proliferation index was markedly higher in ESCC with a positive expression of CXCR4 or CXCL12. Positive CXCL12 expression was significantly correlated with lower recurrence-free survival (RFS, p = 0.02). Cox’s hazard models revealed CXCL12 expression as an independent predictive factor for recurrence. In vitro, CXCL12 exposure or overexpression enhanced ESCC proliferation; and AMD3100, a specific inhibitor of CXCR4, equally decreased proliferation irrespective of CXCL12 exposure or overexpression. In the mouse model, AMD3100 significantly decreased ESCC tumor size (p = 0.03). CXCL12 stimulates ESCC proliferation, and its expression levels are related to lower RFS in patients with ESCC. Our findings indicate that positive CXCL12 expression may be a useful marker for predicting the outcome in patients with ESCC and is a potentially new therapeutic target for ESCC.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology in Japan (24591960, 21591712 and 15K10116)
This publication has 31 references indexed in Scilit:
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastasesEuropean Journal of Cancer, 2010
- Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptorJournal of Molecular Medicine, 2010
- CXCR4 and cancerPathology International, 2010
- CXCR4 mediates the proliferation of glioblastoma progenitor cellsCancer Letters, 2009
- Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary AdenomasClinical Cancer Research, 2008
- SDF-1α Promotes Invasion of Head and Neck Squamous Cell Carcinoma by Activating NF-κBJournal of Biological Chemistry, 2008
- Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancerJournal of Surgical Oncology, 2008
- CXCR4 Regulates Growth of Both Primary and Metastatic Breast CancerCancer Research, 2004
- A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinomaAnnals of Oncology, 2004